Search

Your search keyword '"De Lena M"' showing total 364 results
Start Over Author "De Lena M"
364 results on '"De Lena M"'

6. Evaluation of Web Page Representations by Content Through Clustering

Author

Casillas, Arantza, Fresno, Víctor, de Lena, M. Teresa González, Martínez, Raquel, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Apostolico, Alberto, editor, and Melucci, Massimo, editor

Published
2004
Full Text
View/download PDF

20. EPIRUBICIN vs EPIRUBICIN + CISPLATIN vs EPIRUBICIN + LONIDAMINE vs EPIRUBICIN + CISPLATIN + LONIDAMINE AS FIRST LINE TREATMENT IN ADVANCED BREAST CANCER (BC) PATIENTS. A RANDOMIZED MULTICENTER PHASE III TRIAL WITH A FACTORIAL DESIGN.

Author

Dogliotti, L, Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Alquati, P, De Matteis, A, Nuzzo, F, Giardina, B, Danese, S, De Lena, M, Lorusso, V, Farris, A, Sarobba, M G, DeFabiani, E, Spanu, G, Bonazzi, G, Castiglione, F, Bumma, C, Moro, G, and Galletto, L

Published
2000

27. Six Sigma as a quality improvement tool for academic programs

Author

Cano, Emilio, González de Lena, M., Moguerza, Javier, and Redchuk, Andrés

Subjects
Ingenierías y Tecnologías, high education, six sigma, quality assurance, quality improvement
Abstract

In this work, we present a methodology for the design and improvement of academic programs based on Six Sigma. Six Sigma is a methodology for quality improvement [ISO 13053-1] well known in industrial environments that is being more and more used in services and administration areas. The proposed methodology is applied to the Internal Systems Quality Assurance (ISQA) in Information Technology and Communications (ITC) Schools, but it is easily generalizable to other schools and faculties. The Spanish National Agency for Quality Assessment and Accreditation (ANECA for its Spanish acronym) sets the guidelines for improving the ISQAs, but ANECA does not indicate how to implement them. Currently, there is a lack of methodologies to create and/or improve quality control systems for teaching and associated services. It is therefore necessary to explore other ways. As a first contribution, we are using successful quality improvement methodologies at the business level for academic purposes. Even though there are various methods for improving the quality of processes (EFQM, Kaizen, etc.), Six Sigma has proven to be among the best ones. Indeed, Six Sigma successfully adapted the scientific method in order to be straightforwardly applied to process improvement within organisations. Our second contribution, probably the most important one, is the development of a typology catalogue gathering the developed procedures structure. Such catalogue allows to systematically detect types of procedures and structures, representing by itself a novel tool. The remaining contributions are explicit descriptions of procedures for a particular ITC School. These descriptions showcase a comprehensive practical application of the proposed methodology. The integrated system developed in this work organises the procedures into three areas: strategic, operational and cross-cutting.

Published
2016

28. Concurrent Modulation of 5-Fluorouracil with Methotrexate and L-leucovorin: An Effective and Moderately Toxic Regimen for the Treatment of Advanced Colorectal Carcinoma a Multicenter Phase II Study of the Southern Italy Cooperative Oncology Group

Author

Lorusso, Luigi Manzione, Rossana Casaretti, De Lena M, Giacomo Cartenì, De Lucia L, Giuseppe Comella, S. Mancarella, and Pasquale Comella

Subjects
Adult, Male, Oncology, Antimetabolites, Antineoplastic, Cancer Research, medicine.medical_specialty, Colorectal cancer, Leucovorin, Phases of clinical research, Disease-Free Survival, Drug Administration Schedule, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Mucositis, Humans, Medicine, Aged, Neoplasm Staging, Performance status, business.industry, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Regimen, Methotrexate, Treatment Outcome, Italy, Fluorouracil, 030220 oncology & carcinogenesis, Female, Colorectal Neoplasms, business, Progressive disease, medicine.drug
Abstract

Aims and Background Methotrexate (MTX) and leucovorin (LV) can enhance the cytotoxicity of 5-fluorouracil (5FU) by modifying its metabolic pathway inside target cells. Some preclinical studies and clinical trials have suggested that the concurrent or sequential double modulation of 5FU by means of MTX and LV may give a higher activity than single biochemical modulations. The purpose of our phase II study was to assess the activity and toxicity of a biweekly regimen including MTX, levo-LV and 5FU in colorectal cancer patients. Methods From July 1994 to May 1997, 100 consecutive patients affected by advanced or metastatic colorectal carcinoma were given MTX, 750 mg/m2 iv (2-h infusion) on day 1, and levo-LV, 250 mg/m2 iv (2-h infusion) followed by 5FU, 800 mg/m2 iv bolus on day 2, every two weeks. Patients were treated until complete response or progressive disease was documented, or for a maximum of 16 courses. Results Among 97 eligible patients, 5 complete and 25 partial responses were obtained, giving an overall response rate of 31% (95% exact confidence limits, 22-41%). Response rate was significantly higher in patients with a good (ECOG scale 0) than with a poor (ECOG scale 1 or 2) performance status (40% versus 17%, P Conclusions The double biochemical modulation of 5FU by MTX and levo-LV is at least as effective as, and probably more effective than, the single modulation by MTX or by LV. It may therefore represent a therapeutic option for the palliative treatment of patients with advanced colorectal carcinoma.

Published
1999

29. 'Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium'

Author

Lorusso, V., Crucitta, E., Silvestris, N., Rosati, G., Manzione, L., DE LENA, M., Palmeri, S., Gebbia, V., Mancarella, S., Sobrero, A., Pezzella, G., Comella, P., Mangiameli, A., Muci, D., ITALIAN BLADDER CANCER GROUP, LORUSSO V, CRUCITTA E, SILVESTRIS N, ROSATI G, MANZIONE L, DE LENA M, PALMERI S, GEBBIA V, MANCARELLA S, SOBRERO A, PEZZELLA G, COMELLA P, MANGIAMELI A, MUCI D, and ITALIAN BLADDER CANCER GROUP

Subjects
Paclitaxel, Bladder cancer, Gemcitabine
Abstract

The purpose of the study was to evaluate the antitumor activity and the safety of paclitaxel combined with gemcitabine and cisplatin in patients affected by advanced transitional cell carcinoma of the urothelium (TCC). Eighty-five patients affected by advanced TCC and measurable disease were randomized to receive either paclitaxel at dosage of 70 mg/m2, gemcitabine 1000 mg/m2 and cisplatin 35 mg/m2 on days 1 and 8 every 3 weeks (GCP) or gemcitabine 1000 mg/m2 on days 1, 8, 15 and cisplatin 70 mg/m2 on day 2 every 4 weeks (GC). All enrolled patients were considered evaluable for response and toxicity (intention to treat). The observed response rate was 43% for GCP and 44% for GC combination, respectively. Median time to treatment failure was 32 weeks for GCP and 26 weeks for GC and overall survival 61 vs 49 weeks, respectively (p-value not significant). Grade 3-4 neutropenia was observed in 49% of patients treated with GCP vs 35% of those treated with GC (P=0.05) and grade 3-4 thrombocytopenia was observed in 36% of GCP treated patients as compared to 21% of those treated with GC (P=0.01). Seven patients over 70 years old or with poor PS were removed from the study: 6 patients from GCP group (2 toxic deaths, 2 grade 4 myelotoxicity and 2 grade 3 asthenia) and 1 from GC group was lost to follow-up after the first cycle. The combination of paclitaxel, gemcitabine and cisplatin is effective in the treatment of TCC. However, the addition of paclitaxel to the combination of gemcitabine plus cisplatin seems to increase toxicity, therefore it seems not suitable for poor PS patients and those over 70 years old. Larger and more powered studies are needed to exactly define the role of paclitaxel in this combination.

Published
2005

30. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

Author

DE PLACIDO, SABINO, DE LAURENTIIS, MICHELINO, LAURIA, ROSSELLA, PETRELLA, GIUSEPPE, LIMITE, GENNARO, COSTANZO, RAFFAELE, DE LENA M, LORUSSO V, PARADISO A, D'APRILE M, PISTILLUCCI G, FARRIS A, SAROBBA MG, PALAZZO S, MANZIONE L, ADAMO V, PALMERI S, FERRAU F, PAGLIARULO C, BIANCO AR, GOCSI COOPERATIVE G.R.O.U.P., DE PLACIDO, Sabino, DE LAURENTIIS, Michelino, DE LENA, M, Lorusso, V, Paradiso, A, D'Aprile, M, Pistillucci, G, Farris, A, Sarobba, Mg, Palazzo, S, Manzione, L, Adamo, V, Palmeri, S, Ferrau, F, Lauria, Rossella, Pagliarulo, C, Petrella, Giuseppe, Limite, Gennaro, Costanzo, Raffaele, Bianco, Ar, and GOCSI COOPERATIVE, G. R. O. U. P.

Abstract

The sequential doxorubicin --> CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF x 6 cycles (CMF); (b) doxorubicin x 4 cycles followed by CMF x 6 cycles (A --> CMF); (c) CMF x 6 cycles followed by goserelin plus tamoxifen x 2 years (CMF --> GT); and (d) doxorubicin x 4 cycles followed by CMF x 6 cycles followed by goserelin plus tamoxifen x 2 years (A --> CMF --> GT). The study used a 2 x 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A --> CMF or arms a+c vs b+d) and (2) the effect of adding GT after chemotherapy (arms a+b vs c+d). At a median follow-up of 72 months, A --> CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR)=0.740 (95\% confidence interval (CI): 0.556-0.986; P=0.040) and produced a nonsignificant improvement of overall survival (OS) (HR=0.764; 95\% CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR=0.74; 95\% CI: 0.555-0.987; P=0.040), with a nonsignificant improvement of OS (HR=0.84; 95\% CI: 0.54-1.32). A --> CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients..

Published
2005

34. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group

Author

COMELLA P, CRUCITTA E, DE VITA, Ferdinando, DE LUCIA L, FARRIS A, DEL GAIZO F, PALMERI S, IANNELLI A, MANCARELLA S, TAFUTO S, MAIORINO L, BUZZI F, DE CATALDIS G, CASARETTI R, AVALLONE A, MONTELLA M, COMELLA G, CATALANO G, LORUSSO V, DE LENA M, BIGLIETTO M, SANNA G, SAROBBA MG, BELLI C, RUSSO A, PIZZARDI V, ACCURSO V, MUSCA A, GRAVINA A, LEOPALDI G, BRUNETTI C, MUCI D, LEO S, AVINO F, DE LUCA L, GRECO E, AIELLO C., ORDITURA, Michele, Comella, P, Crucitta, E, DE VITA, Ferdinando, DE LUCIA, L, Farris, A, DEL GAIZO, F, Palmeri, S, Iannelli, A, Mancarella, S, Tafuto, S, Maiorino, L, Buzzi, F, DE CATALDIS, G, Casaretti, R, Avallone, A, Montella, M, Comella, G, Orditura, Michele, Catalano, G, Lorusso, V, DE LENA, M, Biglietto, M, Sanna, G, Sarobba, Mg, Belli, C, Russo, A, Pizzardi, V, Accurso, V, Musca, A, Gravina, A, Leopaldi, G, Brunetti, C, Muci, D, Leo, S, Avino, F, DE LUCA, L, Greco, E, and Aiello, C.

Published
2002

35. 3p microsatellite alterations in exhaled breath condensate from non-small cell lung cancer patients

Author

Carpagnano, GE, Foschino-Barbaro, MP, Mule G., Resta, O, Tommasi, S, Mangia, A, Carpagnano, F, Stea, G, Susca, A, Di Gioia, G, De Lena, M, and Paradiso, A

Subjects
breath condensate, DNA, microsatellite, non-small cell lung cancer, respiratory tract diseases
Abstract

The still-high mortality for lung cancer urgently requires the availability of new, noninvasive diagnostic tools for use in early diagnosis and screening programs. Recently, exhaled breath condensate (EBC) has been proposed as a useful tool to obtain biological information on lung cancer disease. This study provides, for the first time, evidence that DNA alterations already described in lung cancer are detectable in EBC from patients with non-small cell lung cancer (NSCLC) and in healthy subjects. Thirty patients with histologic evidence of NSCLC and 20 healthy subjects were enrolled in the present study. All subjects had allelotyping analysis of DNA from EBC (EBCDNA) and from whole blood (WB-DNA) of a selected panel of five microsatellites (D3S2338, D3S1266, D3S1300, D3S1304, D3S1289) located in chromosomal region 3p. Results from healthy subjects and subjects with cancer, and from EBC and WB, were compared. In addition, the relationships with smoking habit and clinicopathologic tumor features were considered. Microsatellite alterations (MAs) were found in 53% of EBC-DNA and in 10% of WB-DNA loci investigated in patients with NSCLC (p < 10(-6)); conversely, MAs were present only in 13% of EBC-DNA and in 2% of WB-DNA informative loci in healthy subjects. In patients with NSCLC, a direct association between number of MAs detected in EBC-DNA and tobacco consumption was observed. We conclude that EBC-DNA is highly sensitive in detecting MA information unique to patients with lung cancer. Furthermore, MA information seems to be directly related with tobacco consumption, and is potentially applicable to screening and early diagnostic programs for patients with NSCLC.

Published
2005

36. Combination chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5-Fluorouracil versus CNF (Mitoxantrone, Fluorouracil, Cyclophosphamide) in advanced breast cancer. A multicenter randomized study

Author

Lorusso V., De Lena M., Lopez M., Vici P., Piano A., Palomba G., D’Aprile M., Fosser V., Brandi M., Bianco A. R., DE PLACIDO, SABINO, CARLOMAGNO, Chiara, Lorusso, V., De Lena, M., Lopez, M., DE PLACIDO, Sabino, Vici, P., Piano, A., Palomba, G., Carlomagno, Chiara, D’Aprile, M., Fosser, V., Brandi, M., and Bianco, A. R.

Published
1993

39. TRANSPLANTATION BASIC SCIENCE, ALLOGENIC AND XENOGENIC TOLERANCE

Author

Berthelot, L., primary, Robert, T., additional, Tabary, T., additional, Vuiblet, V., additional, Drame, M., additional, Toupance, O., additional, Rieu, P., additional, Monteiro, R. C., additional, Toure, F., additional, Ferrario, S., additional, Cantaluppi, V., additional, De Lena, M., additional, Dellepiane, S., additional, Beltramo, S., additional, Rossetti, M., additional, Manzione, A. M., additional, Messina, M., additional, Gai, M., additional, Dolla, C., additional, Biancone, L., additional, Camussi, G., additional, Pontrelli, P., additional, Oranger, A. R., additional, Accetturo, M., additional, Rascio, F., additional, Gigante, M., additional, Castellano, G., additional, Schena, A., additional, Fiorentino, M., additional, Zito, A., additional, Zaza, G., additional, Stallone, G., additional, Gesualdo, L., additional, Grandaliano, G., additional, Pattonieri, E. F., additional, Gregorini, M., additional, Corradetti, V., additional, Rocca, C., additional, Milanesi, S., additional, Peloso, A., additional, Ferrario, J., additional, Cannone, M., additional, Bosio, F., additional, Maggi, N., additional, Avanzini, M. A., additional, Minutillo, P., additional, Paulli, M., additional, Maestri, M., additional, Rampino, T., additional, Dal Canton, A., additional, Wu, K. S. T., additional, Coxall, O., additional, Luque, Y., additional, Candon, S., additional, Rabant, M., additional, Noel, L.-H., additional, Thervet, E., additional, Chatenoud, L., additional, Snanoudj, R., additional, Anglicheau, D., additional, Legendre, C., additional, Zuber, J., additional, Hruba, P., additional, Brabcova, I., additional, Krepsova, E., additional, Slatinska, J., additional, Sekerkova, A., additional, Striz, I., additional, Zachoval, R., additional, Viklicky, O., additional, Scholbach, T. M., additional, Wang, H.-K., additional, Loong, C.-C., additional, Yang, A.-H., additional, Wu, T.-H., additional, Guberina, H., additional, Rebmann, V., additional, Dziallas, P., additional, Dolff, S., additional, Wohlschlaeger, J., additional, Heinemann, F. M., additional, Witzke, O., additional, Zoet, Y. M., additional, Claas, F. H. J., additional, Horn, P. A., additional, Kribben, A., additional, Doxiadis, I. I. N., additional, Prasad, N., additional, Yadav, B., additional, Agarwal, V., additional, Jaiswal, A., additional, Rai, M., additional, Hope, C. M., additional, Coates, P. T., additional, Heeger, P. S., additional, Carroll, R., additional, Masola, V., additional, Secchi, M. F., additional, Onisto, M., additional, Gambaro, G., additional, Lupo, A., additional, Matsuyama, M., additional, Kobayashi, T., additional, Yoneda, Y., additional, Chargui, J., additional, Touraine, J. L., additional, Yoshimura, R., additional, Vizza, D., additional, Perri, A., additional, Lupinacci, S., additional, Toteda, G., additional, Lofaro, D., additional, Leone, F., additional, Gigliotti, P., additional, La Russa, A., additional, Papalia, T., additional, Bonofilgio, R., additional, Sentis Fuster, A., additional, Kers, J., additional, Yapici, U., additional, Claessen, N., additional, Bemelman, F. J., additional, Ten Berge, I. J. M., additional, Florquin, S., additional, Glotz, D., additional, Rostaing, L., additional, Squifflet, J.-P., additional, Merville, P., additional, Belmokhtar, C., additional, Le Ny, G., additional, Lebranchu, Y., additional, Papazova, D. A., additional, Friederich-Persson, M., additional, Koeners, M. P., additional, Joles, J. A., additional, Verhaar, M. C., additional, Trivedi, H. L., additional, Vanikar, A. V., additional, Dave, S. D., additional, Suarez Alvarez, B., additional, Garcia Melendreras, S., additional, Carvajal Palao, R., additional, Diaz Corte, C., additional, Ruiz Ortega, M., additional, Lopez-Larrea, C., additional, Yadav, A. K., additional, Bansal, D., additional, Kumar, V., additional, Minz, M., additional, Jha, V., additional, Kaminska, D., additional, Koscielska-Kasprzak, K., additional, Chudoba, P., additional, Mazanowska, O., additional, Banasik, M., additional, Zabinska, M., additional, Boratynska, M., additional, Lepiesza, A., additional, Korta, K., additional, Klinger, M., additional, Csohany, R., additional, Prokai, A., additional, Pap, D., additional, Balicza-Himer, N., additional, Vannay, A., additional, Fekete, A., additional, Kis-Petik, K., additional, Peti-Peterdi, J., additional, Szabo, A., additional, Masajtis-Zagajewska, A., additional, Muras, K., additional, Niewodniczy, M., additional, Nowicki, M., additional, Pascual, J., additional, Srinivas, T. R., additional, Chadban, S., additional, Citterio, F., additional, Henry, M., additional, Oppenheimer, F., additional, Lee, P.-C., additional, Tedesco-Silva, H., additional, Zeier, M., additional, Watarai, Y., additional, Dong, G., additional, Hexham, M., additional, Bernhardt, P., additional, Vincenti, F., additional, Rocchetti, M. T., additional, Su owicz, J., additional, Wojas-Pelc, A., additional, Ignacak, E., additional, Janda, K., additional, Krzanowski, M., additional, Su owicz, W., additional, Mitsuhashi, M., additional, Murakami, T., additional, Benso, A., additional, Leuning, D., additional, Reinders, M., additional, Lievers, E., additional, Duijs, J., additional, Van Zonneveld, A. J., additional, Van Kooten, C., additional, Engelse, M., additional, Rabelink, T., additional, Assounga, A., additional, Omarjee, S., additional, Ngema, Z., additional, Ersoy, A., additional, Gultepe, A., additional, Isiktas Sayilar, E., additional, Akalin, H., additional, Coskun, F., additional, Oner Torlak, M., additional, Ayar, Y., additional, Riegersperger, M., additional, Plischke, M., additional, Steinhauser, C., additional, Jallitsch-Halper, A., additional, Sengoelge, G., additional, Winkelmayer, W. C., additional, Sunder-Plassmann, G., additional, Foedinger, M., additional, Kaziuk, M., additional, Kuz'Niewski, M., additional, B Tkowska- Prokop, A., additional, Pa Ka, K., additional, Dumnicka, P., additional, Kolber, W., additional, and Su Owicz, W., additional

Published
2014
Full Text
View/download PDF

40. The role of letrozole (Femara(R)) in breast cancer therapy: A clinical review

Author

Silvestris N, N. Locopo, Crucitta E, De Lena M, and Lorusso

Subjects
Pharmacology, Oncology, Drug, medicine.medical_specialty, Aromatase inhibitor, medicine.drug_class, business.industry, Letrozole, media_common.quotation_subject, medicine.medical_treatment, Cancer, General Medicine, medicine.disease, Breast cancer, Internal medicine, Toxicity, medicine, Pharmacology (medical), business, Adjuvant, Tamoxifen, medicine.drug, media_common
Abstract

Letrozole is a third-generation aromatase inhibitor for use in postmenopausal women with hormonal-sensitive breast cancer. This drug was found to reduce or effectively shrink tumors in a significant number of such patients. It exhibits antitumor activity at a relatively low daily dose, and is highly potent and selective and well tolerated. Results from recent phase III clinical studies have confirmed the efficacy and the key role of this drug in the therapy of advanced breast cancer in postmenopausal women. Moreover, letrozole demonstrated higher activity and lower toxicity compared to tamoxifen in the first-line therapy of postmenopausal women affected with advanced breast cancer. However, it also represents a valid option in second-line therapy after tamoxifen failure. New data on this agent in adjuvant or neoadjuvant treatment also suggest efficacy in the treatment of early breast cancer. This article reviews the clinical data on letrozole in all settings and its future potential in chemoprevention. (c) 2001 Prous Science. All rights reserved.

Published
2003

41. The Mam-1 GOCSI Trial: a Randomised Trial with Factorial Design of Chemo-Endocrine Adjuvant Treatment in Node-Positive (N+) Early Breast Cancer (EBC)

Author

Bianco, Ar, Costanzo, G, DI LORENZO, G, Adamo, Vincenzo, Altavilla, Giuseppe, D'Aprile, M, Palazzo, S, Manzione, L, Farris, A, DE LENA, M, FEDERICO II, U. I. N. V., Naples, Italy, Policlinico, Dazzi, Messina, Italy, MARIA GORETTI, O. S. P. E. D. A. L. E. S., Latina, Italy, OSPEDALE MARIANO SANTO, Cosenza, Italy, Carlo, OSPEDALE S., Potenza, Italy, Oncologia, Medica, Sassari, Italy, Ospedale, Oncologico, and Bari, Italy

Published
2001

44. Transplantation: basic science

Author

Cantaluppi, V., primary, De Lena, M., additional, Beltramo, S., additional, Ferrario, S., additional, Dellepiane, S., additional, Figliolini, F., additional, Bruno, S., additional, Biancone, L., additional, Segoloni, G. P., additional, Tetta, C., additional, Camussi, G., additional, Prasad, N., additional, Jaisawal, A., additional, Yadav, B., additional, Agarwal, V., additional, Tripathi, D., additional, Nunez-Lozano, R., additional, Quiros, Y., additional, Sanchez-Gonzalez, P., additional, Perez de Obanos, M. P., additional, Ruiz, J., additional, Lopez-Hernandez, F. J., additional, Lopez-Novoa, J. M., additional, Yang, J. W., additional, Kim, J. S., additional, Lee, J. Y., additional, Park, H. C., additional, Han, B. G., additional, Choi, S. O., additional, Matsuyama, M., additional, Yoshimura, R., additional, Hayama, T., additional, Chargui, J., additional, Touraine, J.-L., additional, Yoshimura, N., additional, Zanazzi, M., additional, Carta, P., additional, Caroti, L., additional, Antognoli, G., additional, Pinzani, P., additional, Salvianti, F., additional, Villari, D., additional, Minetti, E., additional, Genina, A., additional, Ismail, W., additional, Soliman, A., additional, Ucar, H., additional, Akbas, H. S., additional, Yilmaz, V. T., additional, Aktas, A., additional, Suleymanlar, G., additional, Yucel, G., additional, Cappuccilli, M. L., additional, La Manna, G., additional, Capelli, I., additional, Baraldi, O., additional, Cuna, V., additional, Battaglino, G., additional, Todeschini, P., additional, Feliciangeli, G., additional, Scolari, M. P., additional, Stefoni, S., additional, Loiacono, E., additional, Votta, B., additional, Amore, A., additional, Ranghino, A., additional, Camilla, R., additional, Peruzzi, L., additional, Donadio, M. E., additional, Serriello, I., additional, Gallo, R., additional, Puccinelli, M. P., additional, Coppo, R., additional, Sahin, G., additional, Meltem Akay, O., additional, Uslu, S., additional, Bal, C., additional, Ugur Yalcin, A., additional, Gulbas, Z., additional, and George, J., additional

Published
2013
Full Text
View/download PDF

45. A multicentre, double blind, randomised trial comparing ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis

Author

Gridelli, C., Ianniello, Gp, Ambrosini, G., Mustacchi, Giorgio, Pedicini, T., Farris, A., Iacobelli, S., Rossi, G., Moretti, G., Angelini, F., DE LENA, M., DI CARLO, A., Bonsignori, M., Sabbatini, R., Catalano, G., Rossi, A., Olivieri, A., Fina, P., Bianco, Ar, C., Gridelli, Gp, Ianniello, G., Ambrosini, Mustacchi, Giorgio, T., Pedicini, A., Farri, S., Iacobelli, G., Rossi, G., Moretti, F., Angelini, M., DE LENA, A., DI CARLO, M., Bonsignori, R., Sabbatini, G., Catalano, A., Rossi, A., Olivieri, P., Fina, and Ar, Bianco

Published
1997

47. Transplantation basic

Author

Cantaluppi, V., primary, De Lena, M., additional, Figliolini, F., additional, Beltramo, S., additional, Medica, D., additional, Tognarelli, G., additional, Biancone, L., additional, Tetta, C., additional, Segoloni, G. P., additional, Camussi, G., additional, Pontrelli, P., additional, Cariello, M., additional, Verrienti, R., additional, Tataranni, T., additional, Gigante, M., additional, Loverre, A., additional, Stallone, G., additional, Schena, F. P., additional, Ranieri, E., additional, Gesualdo, L., additional, Grandaliano, G., additional, Coupel, S., additional, Charreau, B., additional, Canet, E., additional, Gerard, N., additional, Segalen, I., additional, Alexandre, N., additional, Grall, A., additional, Jacques-Olivier, P., additional, Hillion, S., additional, Le Meur, Y., additional, Alexandre, H., additional, Dany, A., additional, Michel, D., additional, Denis, G., additional, Christophe, L., additional, Nacera, O., additional, Isabelle, B., additional, Eric, R., additional, Yi Chun, D. X., additional, Buob, D., additional, Grimbert, P., additional, Glowacki, F., additional, Labalette, M., additional, Dufosse, F., additional, Nochy, D., additional, Copin, M.-C., additional, Boleslawski, E., additional, Noel, C., additional, and Hazzan, M., additional

Published
2012
Full Text
View/download PDF

50. Plenary 3

Author

Douillard, J., primary, Rosell, R., additional, De Lena, M., additional, Riggi, M., additional, Hurteloup, P., additional, and Mahe, M., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results